Novellia has successfully raised $18 million in Series A funding to enhance its innovative patient-powered data platform, addressing a significant gap in pharmaceutical research.
The funding round, led by Spark Capital and supported by several prominent investors, brings Novellia's total funding to $28 million. This investment comes as the company launches a new mobile app aimed at empowering patients by providing secure access to their complete health history. Novellia's approach focuses on utilizing real-world data directly sourced from patients, a critical aspect often overlooked in conventional data ecosystems dominated by fragmented datasets from third parties.
Shashi Shankar, the co-founder and CEO of Novellia, emphasizes the importance of centering the patient experience in medical research. The platform aims to streamline patient data collection, reducing the inefficiencies that currently cost the pharmaceutical industry over $50 billion annually. By offering patients a free tool to organize and share their health records, Novellia plans to transform how pharmaceutical companies conduct research and develop new treatments.
With nearly 70% of patients expressing willingness to share their data for research purposes, Novellia is poised to bridge the gap between patient consent and actionable insights for scientists. The company’s AI-driven technology not only aggregates data from various healthcare providers but also employs natural language processing to extract valuable information from unstructured clinical notes. This capability enhances the depth and quality of data available for research, potentially revolutionizing drug development processes.
As Novellia continues to grow, its focus on patient-centric data solutions may redefine the landscape of healthcare research, making it more efficient and inclusive. The implications of this funding and technological advancement could lead to faster medical breakthroughs and improved patient outcomes.